Navigation Links
Misclassified for centuries, medicinal leeches found to be 3 distinct species

Genetic research has revealed that commercially available medicinal leeches used around the world in biomedical research and postoperative care have been misclassified for centuries. Until now, the leeches were assumed to be the species Hirudo medicinalis, but new research reveals they are actually a closely related but genetically distinct species, Hirudo verbana.

The study also shows that wild European medicinal leeches are at least three distinct species, not one. The results appear in the April 10, 2007, online version of the journal Proceedings of the Royal Society B.

"This raises the tantalizing prospect of three times the number of anticoagulants, and three times as many biomedically important developments in areas like protease inhibitors," said Mark Siddall of the American Museum of Natural History, who led the research team. "However, it will also require a better effort to conserve these much-maligned animals, in a way that takes into account their impressive diversity."

While Hirudo medicinalis was approved by the U.S. Food and Drug Administration (FDA) in 2004, for use as a prescription medical device that helps restore blood flow following cosmetic and reconstructive surgery, Hirudo verbana has not been approved by the FDA and has no special conservation status.

"This study is a great example of why the field of taxonomy [the science of classification of organisms] is so important," said Patrick Herendeen, program director in the National Science Foundation (NSF) Division of Environmental Biology, which funded the research. "Taxonomists have been studying the diversity of life on Earth for hundreds of years. In this case, the discovery of previously unknown species diversity has very significant legal and commercial implications."

Since the time of Hippocrates and long before Carolus Linnaeus first described Hirudo medicinalis in 1758, medicinal leeches have been used in a variety of medical treatments--s ome legitimate, many not. Demand for leeches in 19th-century Europe grew so intense that efforts to protect them led to the some of the earliest legislative efforts at biological conservation.

Leeches are still afforded protection by the World Conservation Union (IUCN) and are regulated by the Convention on International Trade in Endangered Species (CITES), the Berne Convention, and the European Union Habitat Directive.

Commercially available European medicinal leeches also are used extensively by biomedical researchers studying biological processes such as blood coagulation, developmental genetics and neurobiology. Studies of commercial specimens have figured prominently in the discovery and production of anticoagulants and protease inhibitors, some of which may have cancer-fighting properties.

That researchers have been mistakenly using Hirudo verbana in their work for decades may call much of this research, including hundreds of scientific publications, into question and force a reconsideration of what scientists think they know about this widely studied species.

Siddall and his colleagues examined mitochondrial and nuclear DNA of wild leeches from across their range in Europe, as well as from samples supplied by commercial providers and university laboratories that use leeches as model organisms.

Their analysis clearly showed that the commercial and laboratory specimens were not Hirudo medicinalis, as they were labeled, but Hirudo verbana. In addition, the work showed that the specimens of wild European medicinal leeches clearly comprised three genetically distinct species.

Source:National Science Foundation

Related biology news :

1. New component of the brakes on nerve regeneration found
2. Strongest proof yet found for prion hypothesis
3. A puzzle piece found in unraveling the wiring of the brain
4. New World founders small in number
5. Norovirus found to cause travelers diarrhea
6. Pair of cancer genes found to drive both cell migration and division
7. Alien woodwasp, threat to US pine trees, found in N.Y.
8. Achilles heel of the herpes virus possibly found
9. Purdue scientists may have found key to halting spinal cord damage
10. Unexpected lock and key mechanism found for the assembly of tumor blood vessels
11. New protein vital for immune response is found in surprise location

Post Your Comments:

(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/4/2015)... November 4, 2015 --> ... report published by Transparency Market Research "Home Security Solutions Market ... Forecast 2015 - 2022", the global home security solutions market is ... by 2022. The market is estimated to expand at ... 2015 to 2022. Rising security needs among customers at ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):
(Date:11/23/2015)... ... ... Noblis, Inc., a leading provider of science, technology, and strategy services, announced ... (NGA), has joined the Noblis NSP team as President of the organization. , ... the private sector,” said L. Roger Mason, Jr., Ph.D. , Senior VP, National ...
(Date:11/23/2015)... and PISCATAWAY, New Jersey ... Cambridge Crystallographic Data Centre (CCDC) announces the ... Structural Database (CSD) and the CSD-System, now complemented ... worldwide: CSD-Discovery to support the discovery of new ... and CSD-Enterprise, the complete set of the CCDC,s ...
(Date:11/23/2015)... , Nov. 23, 2015  CryoLife, Inc. (NYSE: ... focused on cardiac and vascular surgery, announced today that it ... Jaffray Healthcare Conference on Wednesday, December 2, 2015 at The ... . Pat Mackin , President and Chief ... and Chief Executive Officer. --> A live ...
(Date:11/23/2015)... Nov. 23, 2015  Oxis Biotech, Inc. (OXIS), ... [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today ... Cancer Center received notification from the U.S. Food ... with their planned combination Phase 1/Phase 2 clinical ... to develop and commercialize OXS-1550, a novel therapy ...
Breaking Biology Technology: